CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 210 enrolled
Drug / intervention
Dupilumab +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02528214
NCT02528214Phase 3Completed

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Severe Steroid Dependent Asthma

Sanofi·interventional·Posted Aug 19, 2015·Updated Oct 1, 2019

In Brief

A Phase 3 clinical trial evaluating Dupilumab, Placebo, and 4 other interventions for Asthma. Completed, enrolled 210 participants across 80 sites in 17 countries.

Detailed Summary

Primary Objective: To evaluate the efficacy of dupilumab, compared with placebo, for reducing the use of maintenance oral corticosteroids (OCS) in participants with severe steroid-dependent asthma. Secondary Objectives: * To evaluate the safety and tolerability of dupilumab. * To evaluate the effect of dupilumab in improving participants-reported outcomes. * To evaluate dupilumab systemic exposure and the incidence of treatment-emergent antidrug antibodies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesArgentina, Belgium, Brazil, Canada, Chile, Colombia, Hungary, Israel, Italy, Mexico, Netherlands, Poland, Romania, Russia, Spain, Ukraine, United States

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 19, 2015
Enrollment StartOct 15, 2015
Primary CompletionSep 20, 2017
Study CompletionNov 13, 2017
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 10.9 years ago

Interventions

Dupilumabdrug

Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.

Placebodrug

Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.

Oral corticosteroid therapy (prednisone/prednisolone)drug

Oral administration.

Inhaled corticosteroid (ICS) therapydrug

Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy).

Albuterol/Salbutamoldrug

Oral inhalation as needed.

Levalbuterol/Levosalbutamoldrug

Oral inhalation as needed.